Log in

NASDAQ:CUE - Cue Biopharma Stock Price, Forecast & News

$18.01
+0.66 (+3.80 %)
(As of 02/19/2020 02:15 AM ET)
Today's Range
$16.96
Now: $18.01
$18.55
50-Day Range
$13.68
MA: $16.06
$20.00
52-Week Range
$6.10
Now: $18.01
$20.49
Volume185,768 shs
Average Volume223,762 shs
Market Capitalization$414.12 million
P/E RatioN/A
Dividend YieldN/A
Beta1.66
Cue Biopharma, Inc., a biopharmaceutical company, develops biologic drugs for the selective modulation of the human immune system to treat a range of cancers, chronic infectious diseases, and autoimmune disorders. Its lead drug candidate CUE-101, a protein biologic designed to target and activate antigen-specific T cells for human papilloma virus driven cancers. The company offers CUE-102, a non-viral antigen for cancers; CUE-103, an antigen; CUE-200 framework that includes CD80 and/or 4-1BBL to reactivate exhausted T cells and design to enhance antigen-specific T cell for the treatment of chronic infectious diseases; and CUE-300 framework to target various autoimmune diseases. It has collaboration agreements with Merck Sharp & Dohme Corp. for the research and development of its proprietary biologics that target various autoimmune disease indications; LG Chem Life Sciences for Immuno-selective targeting and alteration of T cells (STAT) in the field of oncology; and Albert Einstein College of Medicine to develop Immuno-STAT biologics for chronic infectious diseases. The company was formerly known as Imagen Biopharma, Inc. and changed its name to Cue Biopharma, Inc. in October 2016. Cue Biopharma, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:CUE
CUSIPN/A
Phone617-949-2680

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$1.14 million
Book Value$1.64 per share

Profitability

Net Income$-38,980,000.00
Net Margins-1,437.96%

Miscellaneous

Employees46
Market Cap$414.12 million
Next Earnings Date3/12/2020 (Estimated)
OptionableNot Optionable

Receive CUE News and Ratings via Email

Sign-up to receive the latest news and ratings for CUE and its competitors with MarketBeat's FREE daily newsletter.


Cue Biopharma (NASDAQ:CUE) Frequently Asked Questions

What is Cue Biopharma's stock symbol?

Cue Biopharma trades on the NASDAQ under the ticker symbol "CUE."

How were Cue Biopharma's earnings last quarter?

Cue Biopharma Inc (NASDAQ:CUE) posted its quarterly earnings data on Monday, May, 14th. The company reported ($0.37) EPS for the quarter. Cue Biopharma had a negative net margin of 1,437.96% and a negative return on equity of 148.66%. View Cue Biopharma's Earnings History.

When is Cue Biopharma's next earnings date?

Cue Biopharma is scheduled to release their next quarterly earnings announcement on Thursday, March 12th 2020. View Earnings Estimates for Cue Biopharma.

What price target have analysts set for CUE?

3 analysts have issued 12 month target prices for Cue Biopharma's shares. Their forecasts range from $13.00 to $13.00. On average, they anticipate Cue Biopharma's share price to reach $13.00 in the next year. This suggests that the stock has a possible downside of 27.8%. View Analyst Price Targets for Cue Biopharma.

What is the consensus analysts' recommendation for Cue Biopharma?

3 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Cue Biopharma in the last year. There are currently 3 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for Cue Biopharma.

Has Cue Biopharma been receiving favorable news coverage?

News headlines about CUE stock have been trending positive this week, according to InfoTrie Sentiment. InfoTrie identifies positive and negative media coverage by monitoring more than six thousand news and blog sources. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Cue Biopharma earned a media sentiment score of 2.8 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the next few days. View News Stories for Cue Biopharma.

Who are some of Cue Biopharma's key competitors?

What other stocks do shareholders of Cue Biopharma own?

Who are Cue Biopharma's key executives?

Cue Biopharma's management team includes the folowing people:
  • Mr. Daniel R. Passeri M.Sc., MSc., J.D., CEO, Pres & Director (Age 58)
  • Mr. Colin G. Sandercock J.D., M.Sc., Sr. VP, Gen. Counsel & Sec. (Age 62)
  • Dr. Ronald D. Seidel III, Exec. VP and Head of R&D (Age 43)
  • Dr. Rodolfo J. Chaparro, Exec. VP & Head of Immunology (Age 46)
  • Dr. Steven C. Almo, Co-Founder and Chairman of Scientific & Clinical Advisory Board (Age 58)

Who are Cue Biopharma's major shareholders?

Cue Biopharma's stock is owned by many different of institutional and retail investors. Top institutional shareholders include State Street Corp (1.45%), Crestwood Advisors Group LLC (1.17%), Schroder Investment Management Group (0.40%), Voss Capital LLC (0.40%), Sanders Morris Harris LLC (0.30%) and Bank of New York Mellon Corp (0.29%). Company insiders that own Cue Biopharma stock include Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri and Kerri-Ann Millar. View Institutional Ownership Trends for Cue Biopharma.

Which major investors are selling Cue Biopharma stock?

CUE stock was sold by a variety of institutional investors in the last quarter, including Citigroup Inc., Oxford Asset Management LLP and Bank of America Corp DE. View Insider Buying and Selling for Cue Biopharma.

Which major investors are buying Cue Biopharma stock?

CUE stock was purchased by a variety of institutional investors in the last quarter, including Crestwood Advisors Group LLC, Schroder Investment Management Group, Voss Capital LLC, Sanders Morris Harris LLC, State Street Corp, Russell Investments Group Ltd., Renaissance Technologies LLC and California Public Employees Retirement System. Company insiders that have bought Cue Biopharma stock in the last two years include Anish Suri, Anthony Digiandomenico, Christopher A Marlett, Colin Sandercock, Daniel R Passeri and Kerri-Ann Millar. View Insider Buying and Selling for Cue Biopharma.

How do I buy shares of Cue Biopharma?

Shares of CUE can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity and Charles Schwab.

What is Cue Biopharma's stock price today?

One share of CUE stock can currently be purchased for approximately $18.01.

How big of a company is Cue Biopharma?

Cue Biopharma has a market capitalization of $414.12 million and generates $1.14 million in revenue each year. The company earns $-38,980,000.00 in net income (profit) each year or ($1.94) on an earnings per share basis. Cue Biopharma employs 46 workers across the globe.View Additional Information About Cue Biopharma.

What is Cue Biopharma's official website?

The official website for Cue Biopharma is http://www.cuebiopharma.com/.

How can I contact Cue Biopharma?

Cue Biopharma's mailing address is 21 ERIE STREET, CAMBRIDGE MA, 02139. The company can be reached via phone at 617-949-2680 or via email at [email protected]


MarketBeat Community Rating for Cue Biopharma (NASDAQ CUE)

Community Ranking:  1.6 out of 5 (star)
Outperform Votes:  101 (Vote Outperform)
Underperform Votes:  221 (Vote Underperform)
Total Votes:  322
MarketBeat's community ratings are surveys of what our community members think about Cue Biopharma and other stocks. Vote "Outperform" if you believe CUE will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CUE will underperform the S&P 500 over the long term. You may vote once every thirty days.
This page was last updated on 2/19/2020 by MarketBeat.com Staff

Featured Article: S&P 500 Index

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel